Distributing the COVID-19 vaccine will be unlike previous vaccine distribution efforts due to its scale and urgency.The Coronavirus disease (COVID-19) vaccine will leverage new distribution approaches, so monitoring its physical integrity through the supply chain from manufacturing to point of use will also require fresh thinking. With a lot at stake for all parties involved such as states, regulators, pharmaceutical companies and the general population, the margins for error in delivering a vaccine promptly and with uncompromised efficacy have never been tighter.
Let’s explore the logistics case study of one of the world’s largest pharma companies, the story of how this US-headquartered, globally present pharma giant improved teamwork in their logistics and is now confidently shipping COVID-19 vaccines using cold chain logistics visibility.
The ultimate goal of any pharma company is patient well-being, which it cannot achieve without a tight, lean, and reliable pharma cold chain. When dealing with vaccines for epidemics like the Coronavirus, the pharma cold chain logistics must be planned to maintain a balance between the vaccine reaching safely and on time.Now that the COVID-19 vaccine is here, the objective is to keep it safe and intact through the last mile of its journey and incorporate these best practices to gain control over general vaccine supply chains for human and animal health. Let’s look at how a vaccine travels in the pharma cold chain and how vaccine cold chain monitoring helps make this journey successful.
A vaccine’s journey is more complicated than other pharma products because it is very susceptible to temperature changes, heat and light exposure, and breakage. The COVID-19 vaccine needs an exceptionally reliable cold chain — transport and storage in specific cold temperatures, ambiance control, and impact control to protect from damage — since any deviation may drastically affect the vaccine efficacy and deter on-time, in-full (OTIF) deliveries.